[1] [2] As of 2024, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it remains unavailable as a licensed medicine in the UK
Data was obtained and cited appropriately from included studies in references
As Arizonas premier medical spa, we are dedicated to staying at the forefront of innovation in aesthetic and wellness solutions
GLP-1 (9-36) (human) Product Number: Price range: $104.50 through $181.50 Sequence: H-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH 2 (trifluoroacetate salt) Description GLP-1 (9-36) is a truncated product from the degradation of GLP-1 (7-36) by dipeptidyl peptidase IV (DPP-4)
As exclusivity ends, generic and biosimilar competition is expected to intensify, potentially reducing market share and pricing flexibility for current manufacturers
Earlier studies have hinted towards improved myocardial function with reasonable tolerability in heart failure patients infused with GLP-1 [78]